指南与共识脊柱关节炎

放射学与非放射学中轴型脊柱关节炎患者按现行推荐使用非甾体抗炎药的疗效

Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
指南 / 共识 · Rheumatology (Oxford) · 2016-10-25

本研究纳入未用过抗TNF药物的放射学中轴型脊柱关节炎(AS)与非放射学中轴型脊柱关节炎(nr-axSpA)患者各50例,基线BASDAI≥4且未接受最大剂量NSAID,按现行推荐逐步使用NSAID并随访4周。结果显示两组疗效相似,ASAS40应答率35%、部分缓解率16%,但仅13%患者持续用最大剂量,44%仍有BASDAI≥4。

要点

  • AS与nr-axSpA对NSAID应答率相似,4周ASAS40应答率35%、部分缓解率16%。
  • 仅13%患者持续用最大剂量NSAID,44%患者4周后BASDAI仍≥4。
  • 客观炎症指标(CRP、MRI评分)4周内未显著变化。

核心结论

  • AS与nr-axSpA患者对NSAID的应答率相似,但客观炎症征象4周内未改变。
  • 仅少数患者愿意使用最大剂量NSAID,≥40%患者仍为TNF拮抗剂候选者。

研究设计与样本

  • 连续纳入未用过抗TNF药物的nr-axSpA和AS患者各50例,基线BASDAI≥4且未接受最大NSAID剂量。
  • 若1周后BASDAI仍≥4则换用另一种NSAID,随后3周推荐持续最大剂量,但可因不耐受或改善而减量。
  • 基线及第4周行骶髂关节MRI检查。

主要发现

  • 除CRP和MRI评分外,所有结局在NSAID治疗4周后显著改善,且axSpA亚组间无差异。
  • 第4周ASAS40应答率为35%,部分缓解率为16%。
  • 第4周44%患者BASDAI仍≥4,其中30%已减少NSAID剂量,部分因不耐受(38%)。
  • 仅13%患者持续以最大剂量服用NSAID,但其疗效结局与减量者无差异。

关键数值与推荐

  • ASAS40应答率35%,部分缓解率16%(第4周)。
  • 44%患者第4周BASDAI仍≥4;仅13%患者持续最大剂量NSAID。

临床怎么用

  • AS与nr-axSpA均可按推荐起始NSAID治疗,但需注意仅少数患者能耐受最大剂量。
  • 治疗4周后仍有相当比例患者疾病活动度高,应考虑TNF拮抗剂等后续治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: NSAIDs are first-line therapy in axial SpA (axSpA). The proportion of patients responding to NSAIDs and differences between AS and non-radiographic axSpA (nr-axSpA) in this regard have not been studied in detail to date. The aim of this study was to examine the proportion of patients with AS and nr-axSpA responding to NSAIDs according to current treatment recommendations. METHODS: Consecutive anti-TNF-naïve patients with nr-axSpA and AS (n = 50 each) were included if their BASDAI score was ⩾4 without having received maximal NSAID doses. In case of a BASDAI score ⩾4 1 week later, another NSAID was prescribed. For the next 3 weeks, continuous intake of maximal doses was recommended but patients could reduce doses in case of intolerance or improvement. MRI of the SI joints was performed at baseline and week 4. RESULTS: All outcomes except for CRP and MRI scores improved significantly after 4 weeks of NSAIDs, with no difference between axSpA subgroups. An Assessment of SpondyloArthritis international Society 40% (ASAS40) response and partial remission rates were 35 and 16% at week 4, respectively. At the same time point, a BASDAI score ⩾4 was still present in 44% of patients, 30% of which had reduced NSAID doses, partly due to intolerance (38%). Only 13% of all patients had continuously taken NSAIDs at the maximal dosage, but there was no difference in the efficacy outcome compared with those who had taken reduced doses. CONCLUSION: AS and nr-axSpA patients had similar response rates to NSAIDs while objective signs of inflammation did not change over 4 weeks. Only a minority of patients was willing to take maximal doses of NSAIDs, and ⩾40% patients remained candidates for TNF blockers. These results may influence future trial designs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2016. PMID: 27997346. doi:10.1093/rheumatology/kew367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。